RxDoctor Payments Data

Elenita Benitezpenuelas

Gerontology · Killeen, TXNPI 1194258251

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Amgen at 30.3% of the total. Among gerontology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,908in general payments, 2019–2025

Across 255 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$970
  • Johnson & Johnson$792
  • Novartis$304
  • Pfizer$303
  • Lilly USA, LLC$237
  • plus $817 from 12 others

What the payments were for

  • Food & beverage$4,70896%
  • Education$2004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,908 in reported general payments places this provider in the 90th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$72,613
Medicare patients
220
Services billed
1,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$173,869
RinvoqUpadacitinib22$144,965
OtezlaApremilast21$100,514
Enbrel MiniEtanercept13$95,554
EnbrelEtanercept11$86,638
Hydroxychloroquine Sulfate113$4,943
Pregabalin35$3,762
MethotrexateMethotrexate Sodium76$2,926
Leflunomide21$2,090
Nabumetone40$1,087
Duloxetine Hcl38$950
Gabapentin48$710
Prednisone81$644
Celecoxib27$524
Allopurinol26$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$1,485$187,15232 claims
AbbVieRinvoq$970$144,96522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 gerontology providers in Texas.

Other gerontology in Killeen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →